Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine

[1] Selby P(2019)The value and future developments of multidisciplinary team Cancer care Am Soc Clin Oncol Educ Book 39 332-340

[2] Popescu R(2015)Revisiting Li-Fraumeni syndrome from TP53 mutation carriers J Clin Oncol 33 2345-2352

[3] Lawler M(2017)Inherited TP53 mutations and the Li-Fraumeni syndrome Cold Spring Harb Perspect Med 7 a026187-552

[4] Butcher H(2017)Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition Br J Haematol 176 539-29

[5] Costa A(2018)Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome Curr Opin Oncol 30 23-1557

[6] Bougeard G(2017)Review of clinical next-generation sequencing Arch Pathol Lab Med 141 1544-1239

[7] Renaux-Petel M(2020)High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome J Thorac Oncol 15 1232-112

[8] Flaman JM(2019)A novel heterozygous large deletion of MSH6 gene in a Chinese family with lynch syndrome Gene 704 103-1007

[9] Charbonnier C(2017)Immunohistochemical pitfalls: common mistakes in the evaluation of lynch syndrome Surg Pathol Clin 10 977-1833

[10] Fermey P(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med 375 1823-1830

[1] Selby P(2019)The value and future developments of multidisciplinary team Cancer care Am Soc Clin Oncol Educ Book 39 332-340

[2] Popescu R(2015)Revisiting Li-Fraumeni syndrome from TP53 mutation carriers J Clin Oncol 33 2345-2352

[3] Lawler M(2017)Inherited TP53 mutations and the Li-Fraumeni syndrome Cold Spring Harb Perspect Med 7 a026187-552

[4] Butcher H(2017)Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition Br J Haematol 176 539-29

[5] Costa A(2018)Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome Curr Opin Oncol 30 23-1557

[6] Bougeard G(2017)Review of clinical next-generation sequencing Arch Pathol Lab Med 141 1544-1239

[7] Renaux-Petel M(2020)High prevalence of somatic oncogenic driver alterations in patients with NSCLC and Li-Fraumeni syndrome J Thorac Oncol 15 1232-112

[8] Flaman JM(2019)A novel heterozygous large deletion of MSH6 gene in a Chinese family with lynch syndrome Gene 704 103-1007

[9] Charbonnier C(2017)Immunohistochemical pitfalls: common mistakes in the evaluation of lynch syndrome Surg Pathol Clin 10 977-1833

[10] Fermey P(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer N Engl J Med 375 1823-1830